Latest news with #Onco-InnovationsLimited
Yahoo
16-05-2025
- Business
- Yahoo
Onco-Innovations Celebrates Listing of Common Shares on Cboe Canada
VANCOUVER, BC / / May 16, 2025 / Onco-Innovations Limited (CSE:ONCO) ("Onco" or the "Company") is pleased to announce that it will transfer the listing of its common shares (the "Common Shares") to Cboe Canada Inc. ("Cboe Canada") from the Canadian Securities Exchange ("CSE"). Onco expects its Common Shares to begin trading on Cboe Canada on May 22, 2025 under its existing ticker symbol "ONCO", and the Company has submitted a request to voluntarily delist its Common Shares from the CSE, which is expected to take effect at the close of trading on May 21, 2025. No action is required from shareholders regarding this transition. Cboe Canada, a Tier 1 stock exchange and part of the global Cboe Markets network, offers a robust and internationally recognized platform for innovative companies seeking investor trust, liquidity, and visibility. Since launching in 2015, Cboe Canada has supported issuers through advanced market infrastructure and access to real-time data solutions, including its ETF Market Canada platform - an institutional-grade resource for exploring and analyzing over 1,200 Canadian ETFs. Real-time quotes and market information on Onco-Innovations can be found at "Our move to Cboe Canada is a pivotal step in Onco-Innovations' journey as we scale our operations and deepen our commitment to developing impactful oncology solutions. This listing will not only enhance our visibility within the capital markets but also place us alongside a growing roster of forward-thinking companies focused on long-term value creation. We see this as an opportunity to broaden our investor base, strengthen engagement with institutions, and ensure that our capital strategy evolves in step with our scientific ambitions," stated Thomas O'Shaughnessy, CEO of the Company. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer. ON BEHALF OF ONCO-INNOVATIONS LIMITED, Thomas O'ShaughnessyChief Executive Officer For more information, please contact: Thomas O'ShaughnessyChief Executive OfficerTel: + 1 888 261 8055investors@ The CSE and Cboe Canada have not reviewed and do not accept responsibility for the accuracy or adequacy of this release. Forward-Looking Information This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation, including, without limitation, statements regarding the commencement of trading of the Common Shares on Cboe Canada, the Company's request to voluntarily delist the Common Shares from the CSE, and the Company's future goals and objectives. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain acts, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information, including, without limitation, risks relating to transferring the Company's listing of its Common Shares from the CSE to Cboe Canada, the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all. Accordingly, readers should not place undue reliance on any such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws. SOURCE: Onco-Innovations Limited View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
02-03-2025
- Business
- Associated Press
Onco-Innovations CEO Thomas O'Shaughnessy Featured on Conversations That Matter to Discuss Breakthroughs in Cancer Treatment, AI Integration, and Potential Global Expansion
VANCOUVER, BC / ACCESS Newswire / March 2, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H)(WKN:A3EKSZ) ('Onco' or the 'Company') is pleased to announce that its CEO, Thomas O'Shaughnessy, was recently featured in an exclusive interview on Conversations That Matter, a widely distributed long-form program showcasing thought leaders shaping the world. The program is featured in the Vancouver Sun and is broadcast across multiple television networks in British Columbia, Canada, including CHEK-TV, as well as on digital platforms. In this exclusive interview, O'Shaughnessy shared Onco-Innovations' efforts towards developing a novel treatment candidate for colorectal cancer and other solid tumours, as well as the Company's distinguished scientific team, its recent strategic acquisition of Inka Health AI, and the Company's progress toward advancing clinical trials. The interview delved into Onco-Innovations' pioneering approach to research and development regarding cancer treatment, which focuses on precision medicine to enhance the effectiveness of traditional therapies such as chemotherapy and radiation. O'Shaughnessy highlighted the Company's proprietary technology, developed by leading scientists from the University of Alberta Cancer Institute, including the use of targeted inhibitors and nanotechnology to disrupt cancer cell replication while preserving healthy tissue. He also discussed how the recently-acquired Inka Health AI is developing tools to leverage artificial intelligence to optimize patient identification and enhance clinical trial efficacy. Through this acquisition, he added, Onco-Innovations will continue to focus on building partnerships with research organizations such as Quantify Research, and big-pharma, such as AstraZeneca Canada, collaborations that the Company believes will play a crucial role in advancing a precision medicine approach to cancer therapeutic development. 'Being featured on Conversations That Matter gives us an incredible opportunity to share Onco-Innovations' story and reach a broader audience. It's vital for us to communicate the novel work we're doing in precision cancer therapeutic development and how we're striving to develop innovative therapies,' said Thomas O'Shaughnessy, CEO of Onco-Innovations. 'We are committed to advancing our research, accelerating clinical trials, and ultimately making a global impact in the fight against cancer.' You can watch the interview online at the Conversations That Matter website, their YouTube channel, their Vimeo channel, and the Vancouver Sun website. It will also be broadcast on British Columbia based stations, CHEK-TV, CFTK-TV, CJDC-TV, and CKFR-AM. Please check the individual station websites for specific air dates and times. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer. ON BEHALF OF ONCO-INNOVATIONS LIMITED, 'Thomas O'Shaughnessy' Chief Executive Officer For more information, please contact: Thomas O'Shaughnessy Chief Executive Officer Tel: + 1 888 261 8055 The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release. Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's research initiatives, and the prospects of the Company, including its ability to safeguard its technologies, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'potential', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize any of the Company's technologies, the failure to receive a patent or to otherwise safeguard the Company's intellectual property rights, the failure to successfully complete further trials and studies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
Associated Press
11-02-2025
- Health
- Associated Press
Onco-Innovations' Licensed PNKP Inhibitor Technology Shown to Increase Sensitivity of Cancer Cells to Radiation in Animal Study
VANCOUVER, BC / ACCESS Newswire / February 10, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H ,WKN:A3EKSZ) ('Onco' or the 'Company') is pleased to provide information on its exclusive-licensed technology, a new class of Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitors (the 'Technology'), which demonstrated promising results in enhancing the sensitivity of cancer cells to radiation in an in vivo study 1 (the 'Study') published in December, 2021, entitled, 'Nano-Delivery of a Novel Inhibitor of Polynucleotide Kinase/Phosphatase (PNKP) for Targeted Sensitization of Colorectal Cancer to Radiation-Induced DNA Damage', and carried out by researchers at the University of Alberta, Canada, on tumour-bearing mice. Based on the Study, this Technology has the potential to enhance the landscape of targeted cancer treatments, allowing for more effective therapies that could potentially enhance patient outcomes. The Study demonstrated that Onco's Technology increased the sensitivity of PTEN-deficient cancer cells to radiation in tumour-bearing mice using HCT116 colorectal cancer (CRC) models to a statistically significant degree compared to radiation alone. PTEN is a crucial tumour suppressor gene that helps regulate cell growth. When PTEN is mutated or lost, as it often is in cancer cells, these cells become more prone to uncontrolled growth and are less able to repair damage. 2 By inhibiting PNKP, which is involved in DNA repair, the Technology was shown in the study to weaken the cancer cells' ability to recover from radiation, making them more vulnerable to treatment. This suggests that further testing is worthwhile to explore whether lower doses of radiation could be used in conjunction with the Technology to achieve similar therapeutic effects with the potential benefit of reducing side effects and minimizing harm to healthy tissue. Furthermore, the Study explored the broader implications of this approach. By selectively targeting PNKP in PTEN-deficient cells, the Technology aims to focus on the cancer cells' unique vulnerabilities while sparing normal, healthy cells. This strategy is aimed at developing a more precise and effective way to destroy tumours with less collateral damage, leveraging the weaknesses that arise when both PTEN and PNKP functions are disrupted in cancer cells. ' This Study demonstrated that our Technology has the potential to enhance the effectiveness of radiation therapy specifically in PTEN-deficient tumours; we are accordingly excited to continue pursuing studies toward our mission of paving the way for more targeted and less toxic treatment options and moving Onco towards its goal of becoming a leader in oncology. We are most excited about the future possibilities this Technology holds for improving patient outcomes, " said Thomas O'Shaughnessy, CEO of the Company. About Colorectal Cancer (CRC): Colorectal cancer ('CRC') is the third most common cancer in Canada 3 and the third most common cause of cancer-related death in both men and women in the United States. 4 It is the leading cause of cancer death among men under 50 and ranks second overall in cancer-related deaths. 5 The global incidence of CRC is expected to reach 3.2 million new cases by 2040, driven by aging populations, growth, and development. 6 In the United States, over half (55%) of CRC cases are linked to lifestyle factors, including poor diet, lack of exercise, excessive alcohol consumption, and smoking. 7 In Canada, approximately 26,300 new cases of CRC were reported in 2019, with 9,500 deaths attributed to the disease, indicating a shift towards diagnoses at more advanced stages. 8 The Company also announces that, it has engaged the services of Venture Liquidity Providers Inc. (business address: 1 McGuire Cres. Uxbridge, Ontario, Canada, L9P 1G7, email: [email protected], website: telephone: +1 416-891-4349; and contact: John (JC) Cunningham) ('VLP') to provide market making services, commencing immediately. Under its engagement, VLP will trade common shares of the Company on the Canadian Securities Exchange, and all other trading venues on which the Company's securities may be traded, with the objective of maintaining a reasonable market for the Company's common shares. Under the terms of the engagement, VLP will receive compensation of CAD$5,000 per month, with payment for the initial three (3) months made in advance. The agreement shall continue in force for a period of three (3) months and will automatically renew for successive additional one-month terms unless otherwise terminated in accordance with this agreement. Either party may terminate the agreement with written notice after the initial three-month term. Upon termination, any of the Issuer's prepaid monthly fees in VLP's possession for months in which no trading has occurred will be refunded within 15 business days. There are no performance factors contained in the engagement and VLP will not receive shares or options as compensation. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer. ON BEHALF OF ONCO-INNOVATIONS LIMITED, 'Thomas O'Shaughnessy' Chief Executive Officer For more information, please contact: Thomas O'Shaughnessy Chief Executive Officer Tel: + 1 888 261 8055 The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release. Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Technology, the Company's ability to submit and complete U.S. FDA trials, the ability of VLP to create and maintain a reasonable market for trading of the Company's shares, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'potential', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize the Technology, the failure to complete U.S. FDA clinical trials, the failure to receive regulatory approval in respect of the Technology, the failure of VLP to create or maintain a reasonable market for trading of the Company's shares, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
Associated Press
30-01-2025
- Business
- Associated Press
Onco-Innovations' Licensed Technology Shows Promise in Enhancing Chemotherapy Effectiveness by Overcoming Cancer Cell Resistance and Inhibiting Cancer Cell Repair
VANCOUVER, BC / ACCESS Newswire / January 30, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN: A3EKSZ) ('Onco' or the 'Company') is pleased to provide information on its licensed technology of a new class of PNKP (Polynucleotide Kinase 3'-Phosphatase) inhibitors (the 'Technology') which has demonstrated, in a study[1], the ability to enhance the efficacy of cancer killing inhibitors, known as topoisomerase I poisons, in certain cancer treatments. By enhancing cancer cells' sensitivity to topoisomerase I poisons, this breakthrough technology shows the potential, through further research and development, to one day improve patient outcomes across certain cancers by making chemotherapy more effective while also directly inhibiting cancer cells' ability to repair their own DNA. This innovation holds the potential to become a promising and important part of the expanding global cancer therapy market.[2] 'Our Technology aims to address a critical challenge, which is to overcome drug resistance in cancer treatment and stop cancer cells from being able to repair themselves. With the goal of enhancing the sensitivity of cancer cells to existing therapies, we believe we can continue moving towards improving patient outcomes. That is what drives us in our journey to transform cancer care as we position Onco-Innovations as a key player in a rapidly growing multi-billion-dollar market,' said Thomas O'Shaughnessy, CEO of the Company. Topoisomerase I poisons work by disrupting the DNA replication process in cells, a critical step for cell division. Normally, the enzyme Topoisomerase enzymes cleave the hypercoiled segments of DNA, relax the DNA strands, and then reattach the cleaved ends, thereby allowing the transcription to progress.[3] When topoisomerase I poisons are introduced, they prevent the enzyme from reattaching cut ends, leading to breaks in the DNA that can cause cancer cells to die.[4] However, the challenge with topoisomerase I poisons is that cancer cells can sometimes activate their DNA repair mechanisms to fix the breaks caused by these drugs, which can reduce the overall effectiveness of the treatment. [5] This ability to repair the damage allows some cancer cells to survive and continue proliferating despite the therapy, leading to potential treatment resistance.[6] Human polynucleotide kinase-phosphatase (PNKP) has been recognized as a crucial enzyme in the DNA repair process, particularly following damage caused by ionizing radiation (IR) or topoisomerase I poisons in multiple cancer types, including colorectal cancer (CRC). By targeting PNKP to make cancer cells more sensitive to these drugs, Onco-Innovations' Technology has shown promise in enhancing the effectiveness of these treatments, a therapeutic potential validated by various research groups[7]. This innovative approach holds the promise of one day potentially improving outcomes for patients undergoing cancer therapy. Unlike traditional treatments that often face limitations in targeting resistant cancer cell populations, the Technology has been shown in a study[8] to directly inhibit cancer cells' ability to repair their own DNA, a critical factor in their survival. Conventional treatments frequently fail for several reasons. Radiation therapy, for instance, struggles with poor target definition and can be less effective in tumors that lack sufficient oxygen (hypoxia). Chemotherapy, meanwhile, often faces challenges related to poor drug delivery or the body's inability to properly metabolize the treatment. In both cases, cancer cells are notoriously adept at evading destruction, whether by developing resistance, down-regulating pathways that promote cell death, or through the high sensitivity of normal tissues to these therapies. The ability of cancer cells to repair DNA damage inflicted by these treatments is one of the key factors that allows them to survive and continue proliferating despite ongoing therapy.[9] Onco's novel Technology holds promise in treating tumors that have previously shown resistance to conventional therapies, potentially offering a more effective solution for patients who have exhausted existing options. Moreover, by selectively targeting cancer cells' repair systems, the Technology could potentially minimize the harmful effects on normal tissues, with the goal of further improving patient outcomes. We note that the Company's plans with respect to the Technology include pursuing U.S. Federal Drug Administration Phase I trials, wit the aim of commencing the trials this year. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented groundbreaking technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer. ON BEHALF OF ONCO-INNOVATIONS LIMITED, 'Thomas O'Shaughnessy' Chief Executive Officer For more information, please contact: Thomas O'Shaughnessy Chief Executive Officer Tel: + 1 888 261 8055 The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release. Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Technology, the Company's ability to submit and complete U.S. FDA trials, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'potential', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize the Technology, the failure to complete U.S. FDA clinical trials, the failure to receive regulatory approval in respect of the Technology, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. [1] Front. Oncol., 22 December 2021 Sec. Cancer Molecular Targets and Therapeutics Volume 11 - 2021 | [3] 'All tangled up: how cells direct, manage and exploit topoisomerase function' in Nat Rev Mol Cell Biol. 2011 Nov 23;12(12):827-41. doi: 10.1038/nrm3228. See Section Type IA: single-stranded 'strand-passage' enzymes. [4] Managing DNA's topology to keep genes active. Center for Cancer Research, National Cancer Institute. 2017. Available at: . [6] " Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis.' Journal of clinical oncology: official journal of the American Society of Clinical Oncology vol. 26,17 (2008): 2839-45. [7]Nano-Delivery of a Novel Inhibitor of Polynucleotide Kinase/Phosphatase (PNKP) for Targeted Sensitization of Colorectal Cancer to Radiation-Induced DNA Damage' in Frontiers in Oncology. Volume 11, 2021 Dec 22 11:772920 [8] Front. Oncol., 22 December 2021 Sec. Cancer Molecular Targets and Therapeutics Volume 11 - 2021 |
